natgillin/translations-raw huggingface dataset:
Liver Transplant
41 Presaditev jeter
41 The first dose of oral Mycophenolate mofetil Teva will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines.
Prvi peroralni odmerek zdravila Mofetilmikofenolat Teva boste prejeli vsaj 4 dni po presaditvenem posegu in takoj, ko boste lahko jemali zdravila peroralno.
No data are available to recommend the use of Mycophenolate mofetil Teva in children and adolescents who have received a liver transplant.
Podatki o priporočenem odmerjanju zdravila Mofetilmikofenolat Teva pri otrocih in mladostnikih, ki so prejeli jetrni presadek, niso na voljo.
Method and route of administration Swallow your capsules whole with a glass of water.
Postopek in pot uporabe Pogoltnite cele kapsule z zadostno količino tekočine!
If you take more Mycophenolate mofetil Teva than you should It is important not to take too many capsules.
Če ste vzeli večji odmerek zdravila Mofetilmikofenolat Teva, kot bi smeli:
If you forget to take Mycophenolate mofetil Teva If you forget to take your medicine at any time, take it as soon as you remember, then continue to take it at the usual times.
Če ste pozabili vzeti zdravilo, ga vzemite takoj, ko se spomnite, in nato nadaljujte kot običajno.
If you stop taking Mycophenolate mofetil Teva Do not stop taking Mycophenolate mofetil Teva because you feel better.
Če ste prenehali jemati zdravilo Mofetilmikofenolat Teva:
It is important to take the medicine for as long as the doctor has told you to.
Zdravljenja z zdravilom Mofetilmikofenolat Teva ne prekinjajte, ker se počutite bolje.
Like all medicines, Mycophenolate mofetil Teva can have side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Mofetilmikofenolat Teva neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Very common side effects likely to affect more than 1 in 10 people:  Diarrhoea, vomiting, feeling sick  Decrease in normal amounts of different blood cells, which can result in increased risk of infections, bruising, bleeding, breathlessness and weakness  Bacterial, fungal and viral infections of the digestive and urinary tract, cold sores and shingles
Zelo pogosti neželeni učinki prizadenejo 1 od 10 bolnikov: • Driska, bruhanje, slabost. • Zmanjšano število različnih krvnih celic, ki lahko povzroči povečano tveganje za okužbe, modrice, krvavitve, zasoplost in šibkost. • Bakterijske, glivične in virusne okužbe prebavnega in sečnega trakta, herpes febrilis, pasasti izpuščaj.
Common side effects likely to affect less than 1 in 10, but more than 1 in 100 people:  Changes in different laboratory parameters, including increase in liver enzymes, renal parameters such as creatinine, potassium, blood sugar, blood lipids, cholesterol, phosphates, magnesium, calcium and uric acid  Kidney problems with increased levels of urea  Disorders of the digestive system such as constipation, indigestion, flatulence, belching, inflammation of the mouth, oesophagus, stomach, intestine, liver or pancreas and gastrointestinal bleeding  Convulsions, increased tension in the muscles, shaking and muscle weakness, joint pain
Pogosti neželeni učinki prizadenejo manj kot 1 od 10, vendar več kot 1 od 100 bolnikov: • Spremembe različnih laboratorijskihparametrov, vključno z zvišanimi vrednostmi jetrnih encimov, ledvičnimi parametri, kot so kreatinin, kalij, krvni sladkor, lipidi v krvi, holesterol, fosfataze, magnezij, kalcij in sečna kislina. • Težave z ledvicami z zvišanimi vrednostmi sečnine.
42  Sleeplessness dizziness and headache, tingling or numbness, change of the sense of taste, loss of appetite, weight loss  Inflammation and infections of the respiratory and gastrointestinal tract, sore throat, inflammation of the sinuses, runny and itchy nose  Skin cancer or non cancerous growth of the skin and fungal infections of the skin and vagina  Changes in blood pressure, faster heart beat, dilation of blood vessels  Fluid retention in the body, fever, discomfort, lethargy and weakness  Inflammation of the liver, yellowing of the skin and whites of the eyes
42 • Bolezni prebavil kot so zaprtje, slaba prebava, napenjanje, kolcanje, vnetje ustne sluznice, požiralnika, želodčne sluznice, sluznice tankega črevesa, jeter ali trebušne slinavke in gastrointestinalne krvavitve. • Krči, povečana mišična napetost, tresenje, mišična šibkost, bolečine v sklepih. • Nespečnost, omotičnost in glavobol, šumenje v ušesu ali otrplost, spremenjen okus, izguba apetita, izguba telesne mase. • Vnetja in okužbe dihalnega in prebavnega trakta, vnetje grla, vnetje sinusov, izcedek iz nosu in srbeč nos. • Rak kože ali nerakasta rast kože in glivične okužbe kože in nožnice. • Spremembe krvnega tlaka, hitrejše bitje srca, razširjenje krvnih žil. • Zadrževanje tekočin v telesu, zvišana telesna temperatura, neugodje, otrplost in šibkost. • Vnetje jeter, porumenelost kože in beločnic.
Uncommon side effects likely to affect less than 1 in 100 but more than 1 in 1000 people  Proliferation of the lymphatic tissue, including malignant tumours  Inflammation or infections of the heart and its valves and of the membrane that covers the brain and spinal cord
Občasni neželeni učinki prizadenejo manj kot 1 od 100, vendar več kot 1 od 1. 000 bolnikov: • Rast limfatičnega tkiva, vključno z malignimi tumorji. • Vnetje ali okužbe srca ter srčnih zaklopk in ovojnice, ki loči možgane od hrbtenjače.
Other side effects that have been reported where frequency has not been established  Hypersensitivity (allergic) reactions
Drugi neželeni učinki, kjer pogostnost ni bila ugotovljena: • Preobčutljivostne (alergične) reakcije.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek med jemanjem zdravila Mofetilmikofenolat Teva, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
HOW TO STORE MYCOPHENOLATE MOFETIL TEVA
SHRANJEVANJE ZDRAVILA MOFETILMIKOFENOLAT TEVA
What Mycophenolate mofetil Teva contains:
Kaj vsebuje zdravilo Mofetilmikofenolat Teva
Each capsule contains 250 mg mycophenolate
Vsaka kapsula vsebuje 250 mg mofetilmikofenolata.
The other ingredients are:
- Pomožne snovi so:
Pregelatinised maize starch Povidone K-30 Croscarmellose sodium Magnesium stearate
Kapsula vsebuje: predgeliran koruzni škrob povidon K- 30 premrežen natrijev karmelozat magnezijev stearat
Capsule shells:
Ovojnica kapsule:
Cap:
Pokrovček:
43 Red iron oxide (E172) Yellow iron oxide (E172) Titanium dioxide (E171) Gelatin Black ink containing: shellac, black iron oxide (E172), propylene glycol and potassium hydroxide
43 indigotin (E132) titanov dioksid (E171) želatina Telo: rdeči železov oksid (E172) rumeni železov oksid (E172). titanov dioksid (E171) želatina Črnilo vsebuje: šelak, črni železov oksid (E172), propilenglikol in kalijev hidroksid.
Hard capsules:
Trde kapsule:
Body: caramel opaque, printed ‘ 250’ axially in black ink.
Telo: karamelne barve s črnim napisom “ 250” v smeri osi kapsule.
Cap: light blue opaque printed ‘ M’ axially in black ink.
Pokrovček: svetlo modra s črnim napisom “ M ” v smeri osi kapsule.
Mycophenolate mofetil Teva 250 mg hard capsules are available in PVC/ PVdC -aluminium blisters in pack sizes of 100 or 300 capsules per carton.
Zdravilo Mofetilmikofenolat Teva 250 mg trde kapsule je na voljo v prozornem PVC/ PVdC aluminijastiem pretisnem omotu, v pakiranjih po 100 in 300 kapsul v škatli
Marketing Authorisation Holder Teva Pharma B. V.
Imetnik dovoljenja za promet z zdravilom Teva Pharma B. V.
Manufacturers Teva Pharmaceutical Works Private Limited Company Pallagi út 13 Debrecen H-4042 Hungary
Izdelovalec Teva Pharmaceutical Works Private Limited Company Pallagi út 13 Debrecen H- 4042 Madžarska
TEVA Santé SA Rue Bellocier 89107 Sens France
44 TEVA Santé SA Rue Bellocier 89107 Sens Francija
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) hhtp: / /www. emea. europa. eu
Navodilo je bilo odobreno {XX/ 2008} Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu.
Mycophenolate mofetil Teva 500mg film-coated tablets Mycophenolate mofetil
45 NAVODILO ZA UPORABO Mofetilmikofenolat Teva 500 mg filmsko obložene tablete mofetilmikofenolat
- if you have or ever have had any problems with your digestive system, e. g. stomach ulcers
- če imate ali ste kdaj imeli težave s prebavili, npr. rano na želodcu.
Therefore you should limit your exposure to sunlight and ultra violet (UV) light by wearing appropriate protective clothing and using a sunscreen with a high protection factor.
Ker zdravilo Mofetilmikofenolat Teva zmanjša obrambno sposobnost vašega organizma, obstaja zvečana možnost nastanka kožnega raka, zato se je treba izogibati sončni svetlobi in UV- žarkom z uporabo zaščitnih oblačil in sončne kreme z visokim zaščitnim faktorjem.
Taking other medicines Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste
45 If you answer yes to any of the following questions talk to your doctor before you start to take Mycophenolate mofetil Teva:
Če na katero od spodaj naštetih vprašanj odgovorite pritrdilno, se pred jemanjem zdravila Mofetilmikofenolat Teva posvetujte s svojim zdravnikom.
are sometimes given to patients after a transplant operation), cholestyramine (used to treat patients with high blood cholesterol), rifampicin (antibiotic), antacids, phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate), or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
prejmejo po presaditveni operaciji), holestiramin (uporabljajo ga za zdravljenje bolnikov z visokim holesterolom), rifampicin (antibiotik), antacid, fosfatne vezalce (uporabljajo jih za zmanjšanje absorpcije fosfatov pri bolnikih s kronično ledvično odpovedjo) ali druga zdravila (vključno s tistimi, ki ste jih dobili brez recepta), za katera vaš zdravnik ne ve?
Your doctor should advise you about using contraception before taking Mycophenolate mofetil Teva, whilst taking Mycophenolate mofetil Teva, and for 6 weeks after you have stopped taking Mycophenolate mofetil Teva. Mycophenolate mofetil Teva may cause spontaneous abortions or damage, including problems with development of the ears, to your unborn baby.
Zdravilo Mofetilmikofenolat Teva lahko povzroči spontani splav ali poškoduje vašega (še) nerojenega otroka, vključno z nepravilno razvitostjo ušes.
Your doctor will decide the most appropriate dose based on body surface area (height and weight).
Zdravnik bo določil najbolj ustrezen 2 odmerek glede na telesno površino (višina in telesna masa).
46 Adults:
Odrasli:
The first dose of oral Mycophenolate mofetil Teva will be given to you at least 4 days after the transplant operation and when you are able to swallow oral medicines.
Prvi peroralni odmerek zdravila Mofetilmikofenolat Teva boste prejeli vsaj 4 dni po presaditvenem posegu in takoj, ko boste lahko jemali zdravila peroralno.
The recommended daily dose is 6 tablets (3 g of the active ingredient) taken as 2 separate doses.
47 učinkovine), razdeljenih na 2 posamezna odmerka.
Method and route of administration Swallow your tablets whole with a glass of water.
Postopek in pot uporabe Pogoltnite cele tablete z zadostno količino tekočine.
If you take more Mycophenolate mofetil Teva than you should It is important not to take too many tablets.
Če ste vzeli večji odmerek zdravila Mofetilmikofenolat Teva, kot bi smeli:
Common side effects likely to affect less than 1 in 10, but more than 1 in 100 people:  Changes in different laboratory parameters, including increase in liver enzymes, renal parameters such as creatinine, potassium, blood sugar, blood lipids, cholesterol, phosphates, magnesium, calcium and uric acid  Kidney problems with increased levels of urea  Disorders of the digestive system such as constipation, indigestion, flatulence, belching, inflammation of the mouth, oesophagus, stomach, intestine, liver or pancreas and gastrointestinal bleeding  Convulsions, increased tension in the muscles, shaking and muscle weakness, joint pain  Sleeplessness dizziness and headache, tingling or numbness, change of the sense of taste, loss of appetite, weight loss 47  Inflammation and infections of the respiratory and gastrointestinal tract, sore throat, inflammation of the sinuses, runny and itchy nose  Skin cancer or non cancerous growth of the skin and fungal infections of the skin and vagina  Changes in blood pressure, faster heart beat, dilation of blood vessels  Fluid retention in the body, fever, discomfort, lethargy and weakness  Inflammation of the liver, yellowing of the skin and whites of the eyes
Pogosti neželeni učinki prizadenejo manj kot 1 od 10, vendar več kot 1 od 100 bolnikov: • Spremembe različnih laboratorijskihparametrov, vključno z zvišanimi vrednostmi jetrnih encimov, ledvičnimi parametri, kot so kreatinin, kalij, krvni sladkor, lipidi v krvi, holesterol, fosfataze, magnezij, kalcij in sečna kislina. • Težave z ledvicami z zvišanimi vrednostmi sečnine. • Bolezni prebavil kot so zaprtje, slaba prebava, napenjanje, kolcanje, vnetje ustne sluznice, požiralnika, želodčne sluznice, sluznice tankega črevesa, jeter ali trebušne slinavke in gastrointestinalne krvavitve. • Krči, povečana mišična napetost, tresenje, mišična šibkost, bolečine v sklepih. • Nespečnost, omotičnost in glavobol, šumenje v ušesu ali otrplost, spremenjen okus, izguba apetita, izguba telesne mase. • Vnetja in okužbe dihalnega in prebavnega trakta, vnetje grla, vnetje sinusov, izcedek iz nosu in srbeč nos. • Rak kože ali nerakasta rast kože in glivične okužbe kože in nožnice. • Spremembe krvnega tlaka, hitrejše bitje srca, razširjenje krvnih žil. • Zadrževanje tekočin v telesu, zvišana telesna temperatura, neugodje, otrplost in šibkost. • Vnetje jeter, porumenelost kože in beločnic.
Uncommon side effects likely to affect less than 1 in 100 but more than 1 in 1000 people  Proliferation of the lymphatic tissue, including malignant tumours  Inflammation or infections of the heart and its valves and of the membrane that covers the brain and spinal cord
48 Občasni neželeni učinki prizadenejo manj kot 1 od 100, vendar več kot 1 od 1. 000 bolnikov: • Rast limfatičnega tkiva, vključno z malignimi tumorji. • Vnetje ali okužbe srca ter srčnih zaklopk in ovojnice, ki loči možgane od hrbtenjače.
The active substance is mycophenolate mofetil.
- Zdravilna učinkovina je mofetilmikofenolat.
Each tablet contains 500mg of mycophenolate mofetil.
Vsaka tableta vsebuje 500 mg mofetilmikofenolata.
Microcrystalline cellulose Povidone K-30 Magnesium stearate Croscarmellose sodium
Jedro tablete: mikrokristalna celuloza povidon K- 30 magnezijev stearat premrežen natrijev karmelozat
48 What Mycophenolate mofetil Teva looks like and contents of the pack
Izgled zdravila Mofetilmikofenolat Teva in vsebina pakiranja
Pale purple, oval shaped film-coated tablet, debossed with "M500" on one side and plain on the other side.
49 Temno vijoličaste, filmsko obložene tablete ovalne oblike, z vgraviranim napisom “ M500 ” na eni strani in brez napisa na drugi.
Mycophenolate mofetil Teva 500 mg film-coated tablets are available in PVC/ PVdC -aluminium blisters in pack sizes of 50 or 150 tablets per carton.
Zdravilo Mofetilmikofenolat Teva 500 mg filmsko obložene tablete je na voljo v PVC/ PVdC aluminijastiem pretisnem omotu, v pakiranjih po 50 in 150 tablet v škatli
Computerweg 10, 3542 DR Utrecht The Netherlands
Computerweg 10 3542 DR Utrecht Nizozemska
Debrecen H-4042 Hungary
Izdelovalec Teva Pharmaceutical Works Private Limited Company Pallagi út 13 Debrecen H- 4042 Madžarska
Teva Pharmaceuticals Works Private Limited Company H-2100 Gödöllő Táncsics Mihály ut 82 Hungary
TEVA Pharmaceutical Works Private Limited Company H- 2100 Gödöllő Táncsics Mihály út 82 Madžarska
Teva UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG, UK
TEVA UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG Velika Britanija
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. europa. eu.
Navodilo je bilo odobreno {MM/ LLLL} Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu.
Myfenax is a medicine containing the active substance mycophenolate mofetil.
Zdravilo Myfenax vsebuje zdravilno učinkovino mofetilmikofenolat.
It is available as capsules (250 mg) and tablets (500 mg).
Na voljo je v obliki kapsul (250 mg) ali tablet (500 mg).
Myfenax is a ‘ generic medicine’.
Zdravilo Myfenax je „ generično zdravilo “.
This means that Myfenax is similar to a ‘ reference medicine’ already authorised in the European Union (EU) called CellCept.
To pomeni, da je podobno „ referenčnemu zdravilu “, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu CellCept.
Myfenax treatment should be initiated and maintained by a qualified transplant specialist.
Zdravljenje z zdravilom Myfenax mora uvesti in voditi specialist za presaditve.
The way that Myfenax should be given and the dose depend on the type of organ transplant and the patient ’ s age and size.
Način uporabe zdravila Myfenax in njegovo odmerjanje sta odvisna od vrste presajenega organa ter bolnikove starosti in velikosti.
In children aged between two and 18 years, the dose of Myfenax is calculated depending on height and weight.
Pri otrocih, starih od 2 do 18 let, se odmerek zdravila Myfenax izračuna na osnovi telesne višine in mase.
For liver transplants in adults, mycophenolate mofetil should be given as an infusion (drip into a vein) for the first four days after the transplant, before the patient is switched to 1.5 g Myfenax twice a day as soon as it can be tolerated.
Pri odraslih bolnikih s presajenimi jetri se mofetilmikofenolat prve štiri dni po presaditvi daje kot infuzija (kapalna infuzija v veno), ko je bolnik sposoben požirati pa preide na jemanje 1, 5 g zdravila Myfenax dvakrat na dan.
Myfenax is not recommended for use in children after heart or liver transplants because of a lack of information on its effects in this group.
Uporaba zdravila Myfenax po presaditvi srca ali jeter pri otrocih ni priporočljiva zaradi pomanjkanja informacij o učinkih zdravila v tej starostni skupini.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘ inosine monophosphate dehydrogenase’.
V telesu se pretvori v mikofenolno kislino, ki blokira encim, imenovan „ inozin- monofosfat - dehidrogenaza “.
This enzyme is important for the formation of DNA in cells, particularly in the lymphocytes (a type of white blood cell which is involved in the rejection of organ transplants).
Ta encim je pomemben za tvorbo DNA v celicah, zlasti v limfocitih (vrsti belih krvnih celic, ki sodelujejo pri zavračanju presajenih organov).
By 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Zdravilo Myfenax s preprečevanjem 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non-commercial or commercial purposes, provided the EMEA is acknowledged preventing the production of new DNA, Myfenax reduces the rate at which the lymphocytes multiply.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised for non- commercial or commercial purposes, provided the EMEA is acknowledged tvorbe nove DNA zmanjša hitrost razmnoževanja limfocitov.
Because Myfenax is a generic medicine, studies have been limited to tests to demonstrate that it is bioequivalent to the reference medicine (they produce the same levels of the active substance in the body).
Ker je Myfenax generično zdravilo, so bile študije omejene na teste, s katerimi se lahko dokaže, da je bioekvivalentno referenčnemu zdravilu (zdravili dosegata enake ravni zdravilne učinkovine v telesu).
What are the benefit and risk of Myfenax?
Kakšne so koristi in tveganja, povezana z zdravilom Myfenax?
Because Myfenax is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.
Glede na to, da je Myfenax generično zdravilo in je bioekvivalentno referenčnemu zdravilu, ima enake koristi in tveganja kot referenčno zdravilo.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Myfenax has been shown to have comparable quality and to be bioequivalent to Cellcept.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Myfenax primerljivo raven kakovosti kot zdravilo CellCept in da mu je bioekvivalentno.
Therefore, the CHMP’ s view was that, as for CellCept, the benefit outweighs the identified risk.
Zaradi tega je CHMP menil, da so koristi zdravila Myfenax, tako kot pri zdravilu CellCept, večje od znanih tveganj.
Other information about Myfenax:
Druge informacije o zdravilu Myfenax:
The European Commission granted a marketing authorisation valid throughout the EU for Myfenax to Teva Pharma B. V. on 21 February 2008.
Evropska komisija je dovoljenje za promet z zdravilom Myfenax, veljavno po vsej Evropski uniji, odobrila družbi Teva Pharma B. V. dne 21. februarja 2008.
The full EPAR for Myfenax can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Myfenax je na voljo tukaj.
The full EPAR for the reference medicine can also be found on the EMEA’ s website.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za referenčno zdravilo je na voljo na spletni strani EMEA.
Route of Administration
pretisni omot (PVC/ PVDC/ alu)
Myfenax 250 mg hard capsules
IME ZDRAVILA Myfenax 250 mg trde kapsule
Hard capsule (capsule) The capsule: body is caramel opaque, printed with ‘ 250’ axially in black ink The capsule cap is light blue opaque printed ‘ M’ axially in black ink.
Telo kapsule je karamelne barve s črnim napisom “ 250” v smeri osi kapsule Glava kapsule je svetlo modra s črnim napisom “ M ” v smeri osi kapsule.
Adults: oral Myfenax should be initiated within 72 hours following transplantation.
Zdravilo Myfenax damo uvodoma peroralno v 72 urah po presaditvi.
Myfenax capsules should only be prescribed to patients with a body surface area of at least 1.25 m2.
Kapsule zdravila Myfenax lahko predpišemo samo bolnikom, katerih
Patients with a body surface are of 1.25 to 1.5 m2 may be prescribed Myfenax capsules at a dose of 750 mg twice daily (1.5 g daily dose).
Bolnikom s telesno površino med 1, 25 in 1, 5 m predpišemo kapsule zdravila Myfenax v odmerku 750 mg dvakrat na dan (dnevni odmerek 1, 5 g).
Patients with a body surface area greater than 1.5 m2 may be prescribed Myfenax capsules at a dose of 1 g twice daily (2 g daily dose).
Bolnikom s telesno površino 2 nad 1, 5 m predpišemo kapsule zdravila Myfenax v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
Adults: oral Myfenax should be initiated within 5 days following transplantation.
2 Odrasli: v začetku damo zdravilo Myfenax peroralno v 5 dneh po presaditvi.
2 Children and adolescents: no data are available for paediatric cardiac transplant patients, therefore use in this patients group is not recommended until further data to support this is available.
Otroci in mladostniki: za otroke s srčnim presadkom podatki niso znani, zato uporaba zdravila Myfenax v tej starostni skupini ni priporočljiva, dokler ne bodo na voljo zadostni podatki.